$0.72
+0.00 (+0.03%)
Open$0.72
Previous Close$0.72
Day High$0.74
Day Low$0.69
52W High$20.00
52W Low$0.64
Volume—
Avg Volume174.8K
Market Cap5.67M
P/E Ratio—
EPS$-13.92
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,221.7% upside
Current
$0.72
$0.72
Target
$16.67
$16.67
$13.69
$16.67 avg
$25.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 19.35M | 586.6K | 551.3K |
| Net Income | -166,902,221 | -23,280 | -22,798 |
| Profit Margin | -862.3% | -4.0% | -4.1% |
| EBITDA | -167,722,740 | -32,929 | -31,435 |
| Free Cash Flow | — | -20,426 | -16,844 |
| Rev Growth | +212.6% | +23.9% | +11.9% |
| Debt/Equity | — | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |